Related Experiment Videos
Islet allotransplantation in type 1 diabetic patients
1Surgical and Medicine Department, Dibit, Vita-Salute University, S. Raffaele Scientific Institute, Milan, Italy. bertuzzi.federico@hsr.it
Minerva Endocrinologica
|April 30, 2003
Summary
Islet transplantation shows promise for type 1 diabetes, with improved outcomes due to new immunosuppression. However, donor scarcity and long-term graft function remain challenges for widespread use.
Area of Science:
- Endocrinology
- Transplantation immunology
Background:
- Islet transplantation offers a potential cure for type 1 diabetes by restoring glucose homeostasis.
- Early attempts faced challenges with low insulin independence and graft survival rates.
Purpose of the Study:
- To evaluate the efficacy of novel immunosuppression strategies in islet transplantation for type 1 diabetes.
- To assess long-term graft function and insulin independence in recipients.
Main Methods:
- Transhepatic percutaneous islet injection under local anesthesia.
- Implementation of new immunosuppression protocols.
- Monitoring of glucose homeostasis and graft function post-transplant.
Main Results:
- Recent advancements in immunosuppression significantly improved clinical outcomes.
- Achieved insulin independence in all recipients, with over 70% maintained at 2 years.
- Identified limitations including the need for immunosuppression and donor organ availability.
Conclusions:
- Islet transplantation is a viable option for select type 1 diabetes patients, particularly those with brittle diabetes.
- Ongoing research is needed to address long-term graft survival and donor limitations.
- Improved immunosuppression has made islet transplantation more effective but indications remain restricted.